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Key points
 The cardiacmetabolic reprogramming seen in heart diseases such asmyocardial infarction and
hypertrophy shares similarities with that seen in chronic hypoxia, but understanding of how
the hypoxic heart responds to further hypoxic challenge – hypoxic tolerance – is limited.
 The pyruvate dehydrogenase complex serves to control irreversible decarboxylation of pyruvate
within mitochondria, and is a key regulator of substrate metabolism, potentially regulating
hypoxic tolerance.
 Acute activation of the pyruvate dehydrogenase complex did not improve cardiac function
during acute hypoxia; however, simultaneous activation of the pyruvate dehydrogenase
complex during chronic hypoxic exposure improved tolerance to subsequent acute hypoxia.
 Activation of the pyruvate dehydrogenase complex during chronic hypoxia stockpiled cardiac
acetylcarnitine, and this was used during acute hypoxia. This maintained cardiac ATP and
glycogen, and improved hypoxic tolerance as a result.
 These findings demonstrate that pyruvate dehydrogenase complex activation can improve
cardiac function under hypoxia.
Abstract The pattern of metabolic reprogramming in chronic hypoxia shares similarities with
that following myocardial infarction or hypertrophy; however, the response of the chronically
hypoxic heart to subsequent acute injury, and the role of metabolism is not well understood.
Here,wedetermined themyocardial tolerance of the chronically hypoxic heart to subsequent acute
injury, and hypothesised that activation of a key regulator ofmyocardialmetabolism, the pyruvate
dehydrogenase complex (PDC), could improve hypoxic tolerance. Mouse hearts, perfused in
Langendorff mode, were exposed to 30 min of hypoxia, and lost 80% of pre-hypoxic function
(P = 0.001), with only 51% recovery of pre-hypoxic function with 30 min of reoxygenation
(P= 0.046). Activation of the PDC with infusion of 1 mM dichloroacetate (DCA) during hypoxia
and reoxygenation did not alter function. Acute hypoxic tolerance was assessed in hearts of mice
housed in hypoxia for 3 weeks. Chronic hypoxia reduced cardiac tolerance to subsequent acute
MichalK.Handzlik is currently a Senior Fellow at theMitochondria andMetabolismCentre at the University ofWashington in
Seattle,WA, USA. His research interests are in the field of cardiac energymetabolism. Following earning a BSc in Physiotherapy
from the University School of Physical Education (AWF) in Wroclaw, Poland, he received his MSc in Exercise Physiology at
Loughborough University, UK, and a PhD in Biomedical Sciences from the University of Nottingham, UK in the laboratory of
Dr Mark A. Cole.
C© 2018 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society DOI: 10.1113/JP275357
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution
and reproduction in any medium, provided the original work is properly cited.
2 M. K. Handzlik and others J Physiol 000.0
hypoxia, with recovery of function 22% of pre-acute hypoxic levels vs. 39% in normoxic control
hearts (P = 0.012). DCA feeding in chronic hypoxia (per os, 70 mg kg−1 day−1) doubled cardiac
acetylcarnitine content, and this fell following acute hypoxia. This acetylcarnitine use maintained
cardiac ATP and glycogen content during acute hypoxia, with hypoxic tolerance normalised. In
summary, chronic hypoxia renders the heart more susceptible to acute hypoxic injury, which
can be improved by activation of the PDC and pooling of acetylcarnitine. This is the first study
showing functional improvement of the chronically hypoxic heart with activation of the PDC,
and offers therapeutic potential in cardiac disease with a hypoxic component.
(Received 30 September 2017; accepted after revision 19 January 2018; first published online 31 January 2018)
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Introduction
Altered cardiac energy metabolism is an integral
component of the aetiology and progression of heart
failure. An increased reliance on carbohydrate as a source
of ATP re-synthesis and suppressed oxidative metabolism
are observed in myocardial hypertrophy and following
myocardial infarction (Allard et al. 1997; Davila-Roman
et al. 2002; Osorio et al. 2002; de las Fuentes et al. 2003;
Heather et al. 2006), and these impair the heart’s total
ATP generating capacity (Neubauer, 2007). Development
of myocardial hypoxia is also a characteristic of the
contributing factors to heart failure and is observed in
myocardial hypertrophy (Sano et al. 2007; Karamitsos
et al. 2013; Mahmod et al. 2014). The pattern of metabolic
reprogramming seen with sustained hypoxia shares many
similarities with that seen in the metabolic remodelling
following myocardial infarction, which includes a fall in
the rates of fatty acid oxidation, increased glycolysis and
depressed mitochondrial ATP generation (Heather et al.
2012; Cole et al. 2016; Mansor et al. 2016).
The link between myocardial hypoxia and the
development of heart failure is recognised, but there is
limited informationonhow functionally tolerant theheart
is to hypoxia, and studies are conflicting. Recently, the
finding that severe, chronic hypoxia improved function
following myocardial infarction (Nakada et al. 2017)
further questions cardiac tolerance to oxygen restriction.
Animals, either naturally resident at altitude (Schippers
et al. 2012) or regularly exposed to hypoxia (Bing
et al. 1972), show cardiac adaptation with an increased
emphasis on glycolysis for ATP supply, and an increased
tolerance to hypoxia. However, in naive hearts exposed
to chronic hypoxia, the information is conflicting, in that
tolerance to global ischaemia following prolonged hypo-
xia is reported to be either unchanged (Asemu et al. 1999),
improved (Guo et al. 2009) or impaired (Milano et al.
2010). Interpretation is further complicated by the use
of different chronic hypoxic protocols, in both neonatal
and adult animals. Evidence describing tolerance of the
chronically hypoxic heart to subsequent acute hypoxia
is equally inconsistent (Silverman et al. 1997; Milano
et al. 2002; La Padula & Costa, 2005). Recently, we have
developed and characterised a moderate hypoxic protocol
(Heather et al. 2012; Cole et al. 2016; Mansor et al.
2016), which involves a period of acclimation similar to
that employed by humans in transition to high altitude
(Holloway et al. 2011). In this model, baseline myo-
cardial functionwas unaffected, underpinned by extensive
metabolic reprogramming, but disruptionof this apparent
adaptation resulted in cardiac dysfunction (Cole et al.
2016; Mansor et al. 2016). More detailed information on
cardiac responses tohypoxia is thereforeneeded inorder to
potentially offer therapies for cardiacdiseaseby identifying
intermediate metabolic targets.
Chronic hypoxia results in increased glycolytic flux
(Cole et al. 2016; Mansor et al. 2016), and a fall
in mitochondrial respiration (Heather et al. 2012).
Mitochondrial use of pyruvate, the end-product of
glycolysis, is regulated by the mitochondrial pyruvate
dehydrogenase complex (PDC). The PDC catalyses the
oxidative decarboxylation of pyruvate to acetyl coenzyme
A (acetyl-CoA) and by doing so serves to regulate
mitochondrial carbohydrate use. PDC activation is
covalently regulatedby a family of pyruvate dehydrogenase
kinases (PDK1–4) and a family of pyruvate dehydrogenase
phosphatases (PDP1–2) (Bowker-Kinley et al. 1998;
Huang et al. 1998). However, despite full activation of
the PDC complex, flux through the PDC reaction can be
inhibited by allosteric regulation (Constantin-Teodosiu
et al. 1993). Reduced PDC activity and flux have been
reported in infarcted or failing hearts (Seymour &
Chatham, 1997; Dodd et al. 2014), and acute hypoxia is
known to reduce PDC activity in skeletal muscle (Parolin
et al. 2000) and in mouse embryonic fibroblasts for up
to 96 h (Kim et al. 2006). Therefore inhibition of PDC
activity andfluxduringprolongedhypoxia could therefore
be expected but is currently undetermined.
PDC activity and flux can be acutely increased with
the PDK inhibitor dichloroacetate (DCA) (Whitehouse &
Randle, 1973; Atherton et al. 2011). Acutely,DCAhas been
shown to improve cardiac function following ventricular
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fibrillation (Azam et al. 2015) and following global
ischaemia in healthy and hypertrophied hearts (McVeigh
& Lopaschuk, 1990; Randall et al. 1998; Wambolt et al.
2000; Ussher et al. 2012), associated with an increase in
glucose oxidation. Whether similar effects are apparent
during acute hypoxia, rather than the anoxic conditions
of ischaemia is unknown. Furthermore, the impact of
chronic PDC activation on cardiac adaptation to hypoxia
is also unresolved. However, the impaired PDC activity
seen in the diabetic heart (Seymour & Chatham, 1997)
can be normalised with chronic DCA treatment (Le Page
et al. 2015), and improves diastolic function. Therefore,
assuming cardiac PDC activity is suppressed with chronic
hypoxia, prolonged stimulation of the PDC may be
beneficial.
We hypothesised, consistent with the available
information from ischaemic studies, that acute hypo-
xic injury could be improved by pharmacologically
increasing PDC activity and flux. In chronic hypoxia,
we hypothesised that PDC activity and flux would be
suppressed, which in turn would reduce the tolerance
of the chronically hypoxic heart to an additional hypo-
xic challenge. We further hypothesised that increasing
PDC activity and flux during prolonged hypoxia would
offset the impairment of mitochondrial ATP production
and functional impairment associated with chronic
hypoxia.
Methods
Ethical approval
All animal experiments were approved by the University
of Nottingham animal welfare committee, compliant with
the UK Home Office Animals (Scientific Procedures) Act,
1986, and amended by European Directive 2010/63/EU.
The work conformed to The Journal of Physiology’s
principles and regulations as described in the checklist
of Grundy (2015).
Animals
Eight-week-old outbred male CD1 mice were purchased
from a commercial breeder (Harlan, UK). Animals were
housed on a 12 h light/dark cycle, fed ad libitum and kept
under controlled conditions of temperature and humidity.
Acute hypoxia
Animals were killedwith a terminal dose of sodiumpento-
barbitone (60 mg (kg body weight)−1 I.P.) and the heart
excised and arrested in ice-cold Krebs–Henseleit (KH)
buffer containing (mM): 118 NaCl, 4.7 KCl, 1.2 MgSO4,
1.85 CaCl2, 0.5 Na2EDTA, 11.0 glucose, 25.0NaHCO3 and
1.2 KH2PO4. Hearts (n= 7) were perfused in Langendorff
mode at 80 mmHg constant pressure with 200 mL
recirculating KH buffer containing 0.4 mM palmitate
pre-bound to 3% bovine serum albumin. The buffer
was continually gassed with a mix of 95% O2 and 5%
CO2, with the temperature maintained at 37°C. Cardiac
function was measured continuously using a polyethylene
balloon placed within the left ventricular lumen inflated
to 4–8 mmHg, determining developed pressure (DP)
and heart rate (HR). Rate pressure product (RPP) was
calculated from the product of HR and DP. Following
30 min of baseline perfusion, hearts were subjected to
30 min hypoxia by replacing 95% O2 with 95% N2.
This reduced buffer [O2] to one-fifth of normoxic levels.
Hearts were then returned to normoxia (reoxygenation)
for 30 min. Experiments had three end points, with hearts
flash frozen following pre-hypoxic perfusion (n = 7),
end-hypoxia (n = 7) and end-reoxygenation (n = 7), and
stored at −80°C for subsequent analysis. In a separate
group of experiments, 1 mM DCA (Sigma, St Louis, MO,
USA) was infused to increase cardiac PDC activity either
during hypoxia (DCA Hypox/Reox, n = 8) or from the
onset of reoxygenation (DCA Reox, n = 7).
Chronic hypoxic exposure
Mice (n = 26) were housed for 21 days in a normobaric
hypoxic chamber (Medical Engineering Unit, University
of Nottingham, UK). Chamber oxygen level (inspired
O2 fraction, F iO2) was regulated via a hypoxic generator
(Hypoxico, New York, NY, USA). As described pre-
viously, F iO2 was reduced from 21% to 11% over 7 days
and subsequently maintained at 11% for 14 days (Cole
et al. 2016). Chamber CO2 levels did not exceed 0.1%.
A separate group of mice (n = 24) were fed DCA
per os in drinking water throughout hypoxic housing
(0.75 g L−1 neutralised to pH 7.4 with NaOH) resulting
in a dose of 70 mg kg−1 day−1. A further group of
normoxic animals (n= 25)were housed in the same room.
Following removal from the hypoxic chamber, in order
to stabilise cardiac function, mice breathed room air for
1 h, prior to being killed and heart perfusion as described
above.
Cardiac metabolic flux
Cardiac glycolytic flux was determined in isolated beating
hearts as previously described (Cole et al. 2016). Briefly,
[5-3H]glucose (Perkin Elmer, Chalfont, Bucks, UK) was
added to KH buffer and paired aliquots of recirculating
buffer were collected at 5 min intervals during heart
perfusion. Conversion of [3H]glucose to 3H2O was
determined using Dowex anion separation. Net cardiac
lactate efflux was determined following assay of timed
buffer collections as previously described (Lundholm
et al. 1963).
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Pyruvate dehydrogenase activity assay
Five to 10 milligrams of frozen tissue was used
to determine PDC activity as previously described
(Constantin-Teodosiu et al. 1991b). Briefly, PDC activity
in its dephosphorylated active form (PDCa) was assayed
in a buffer containing NaF and dichloroacetate (DCA),
and was expressed as a rate of acetyl-CoA formation
(μmol min−1 (mg wet tissue)−1 at 37°C).
Tissue metabolites
Left ventricular tissue was lyophilised and powdered.
Muscle acetylcarnitine was determined using a radio-
enzymatic method (Cederblad et al. 1990). Myocardial
ATP, ADP, AMP, lactate, total creatine and glycogen were
determined using previously described methods (Harris
et al. 1974). The total adenine nucleotide (TAN) pool
was calculated as a sum of ATP, ADP and AMP. The
energy charge of the cell was calculated using the following
formula, using the method of Atkinson &Walton (1967):
Energy charge = [ATP] +
1
2 [ADP]
[ATP] + [ADP] + [AMP]
Western blotting
Analiquotof the left ventriclewashomogenised in ice-cold
buffer containing 50 mM Tris-HCl, pH 7.5, 1 mM EDTA,
1 mM EGTA, 1% IGEPAL, 0.1% β-mercaptoethanol and
10 μL mLbuffer−1 protease inhibitor cocktail. Tissue lysate
was centrifuged at 13,000 g for 10minat 4°Cand the super-
natant stored at−80°C. Homogenate protein content was
determined using a bicinchoninic acid assay (Pierce, UK).
Protein samples were run on a 12% Bis-Tris acrylamide
gel for 2 h at constant 100 V and transferred to a
polyvinylidenedifluoride (PVDF) membrane for 2 h at
constant 250mA in a cooled transfer tank. Themembrane
was blocked for 1 h and incubated overnight at 4°C with
rabbit anti-PDK1 antibody (Cell Signaling, Leiden, the
Netherlands), rabbit anti-PDK2 antibody (Abgent, San
Diego, CA, USA), rabbit anti-PDK4 (Abgent, San Diego,
CA, USA) and rabbit anti-actin antibody (Sigma-Aldrich,
Gillingham, Dorset, UK). Membranes were then washed
and incubated with goat anti-rabbit HRP-conjugated
secondary antibody (R&D Systems, Abingdon, Oxon,
UK). Washed membranes were incubated with enhanced
chemiluminesence detection solution (Amersham, Bucks,
UK) and exposed to X-ray film (Kodak, Watford, UK).
Statistical analysis
Repeated measures ANOVA of mixed design was used
to test for differences between groups over time.
When significant, Sidak post hoc tests were subseq-
uently performed on individual comparisons. Statistical
significance was set at P 0.05 for all analyses, with results
presented as mean ± standard error of mean.
Results
DCA infusion during acute hypoxia and
reoxygenation does not affect cardiac function
The effects of 30 min of hypoxia on cardiac function,
and the influence of DCA infusion during acute hypo-
xia and reoxygenation were determined compared to
control hearts (Fig. 1A–C). In control hearts, cardiac
function fell steadily throughout acute hypoxia, with a
60% fall in DP (P = 0.003) and an 80% fall in RPP
after 30 min (P = 0.001). Reoxygenation resulted in
only partial functional recovery, to 51% of pre-hypoxic
RPP (P = 0.046). DCA infusion throughout hypoxia and
reoxygenation (DCA Hypox/Reox), or DCA infusion at
the onset of reoxygenation (DCA Reox) did not alter
end-hypoxic function, or recovery from hypoxia.
In control hearts, acute hypoxia resulted in a doubling
of PDC activity (Fig. 1D, P = 0.001), returning to
baseline values following reoxygenation. DCA infusion
during acute hypoxia increased PDC activity 4-fold by
the end of hypoxia (P = 0.008), and with sustained DCA
infusion,was still 2-foldhigherby the endof reoxygenation
(DCA Hypox/Reox, P = 0.002). Infusion of DCA during
reoxygenation alone (DCA Reox) increased PDC activity
8-fold compared to control hearts (P = 0.001). In
control hearts, acute hypoxia reduced cardiac acetyl-
carnitine content (Fig. 1E) by 59% at the end of acute
hypoxia relative to pre-acute hypoxia (P = 0.001), and
acetylcarnitine recovered to pre-hypoxic levels by the
end of reoxygenation. In contrast to the 4-fold rise
in PDC activity with DCA infusion throughout acute
hypoxia and reoxygenation, acetylcarnitine only rose by
71% in acute hypoxia compared to control hearts, and
was 80% higher by the end of reoxygenation. DCA
infusion during reoxygenation alone increased acetyl-
carnitine concentration by 48% (P = 0.017) relative to
control hearts at the same time point.
Lactate efflux in control hearts (Fig. 1F) increased
2.5-fold during acute hypoxia (P = 0.001), returning to
near the pre-hypoxic rate with reoxygenation. In contrast,
infusion of DCA during hypoxia resulted in lactate efflux
being no different from the pre-hypoxic rate, and the rate
at the end of reoxygenation fell compared to control hearts
at the same time point (P = 0.001). DCA infusion during
reoxygenation alone also reduced lactate efflux relative to
control hearts at the same time point (P = 0.003). Fatty
acid oxidation fell by 75%with 30min of hypoxia (Fig. 1G,
P= 0.025) andwas unaffected byDCA infusion.However,
whilst fatty acid oxidation in control hearts recovered to
pre-hypoxic levels with reoxygenation, hearts infusedwith
DCA either throughout hypoxia and reoxygenation, or in
C© 2018 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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the reoxygenation period alone, had 35% lower fatty acid
oxidation than control hearts (P = 0.047).
Chronic hypoxia results in reduced tolerance
to acute hypoxia
Micehoused inhypoxic conditions for 3weeksmaintained
body weight (Table 1) and had calorific intake no
different to normoxic control animals (data not shown).
Blood haemoglobin concentration was 71% greater in
hypoxic mice (P = 0.001). Cardiac function of iso-
lated hearts from chronically hypoxic mice (Fig. 2A–C)
was no different from normoxic controls, with normal
coronary flow rates (Table 1). Acute hypoxia reduced DP
of hearts from previously normoxic mice by 64% (Fig. 2A,
P = 0.001), which was no different to that seen in control
hearts in the previous acute DCA study (Fig. 1A), and
recovery of function following reoxygenation was also
similar to the previous acute study. However, hearts from
chronically hypoxic mice were less tolerant of acute hypo-
xia, end-hypoxic DP being lower than in hearts from
normoxic controls (P = 0.014), and final recovery of DP
following reoxygenation was 34% of pre-hypoxic levels,
whilst control hearts recovered to 65% (P = 0.001).
Heart rate was no different between groups during acute
hypoxia, and as a result end-hypoxic RPP was lower in
hearts from chronically hypoxic animals and recovery of
RPP was impaired relative to normoxic controls (22% vs.
39%, P = 0.012, Fig. 2C and D). End-diastolic pressure
(EDP) had increased 15-fold by the end of acute hypoxia
in hearts from normoxic controls (Fig. 2E, P = 0.001),
falling slightly with reoxygenation (25%, P = 0.007). In
contrast, EDP of hearts from chronically hypoxic animals
did not fall with reoxygenation, being unaltered relative to
normoxic controls at the end of acute hypoxia.
DCA improves hypoxic tolerance of the chronically
hypoxic heart
Body weight of chronically hypoxic animals was 8% lower
in the DCA-fed group relative to normoxic controls (P =
0.002), but was unaltered relative to chronically hypoxic
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Figure 1. Effect of acute hypoxia (grey bar) and dichloroacetate (DCA) infusion on cardiac function and
metabolism (n = 7)
Developed pressure (A), heart rate (B), rate pressure product (C), cardiac pyruvate dehydrogenase complex (PDC)
activity (D), cardiac acetylcarnitine content (E), lactate efflux (F) and fatty acid oxidation (G). Hearts were flash
frozen at the end of pre-acute hypoxia, acute hypoxia and reoxygenation for subsequent analysis of metabolites.
DCA Hypox/Reox, 1 mM DCA continuously infused from the onset of hypoxia; DCA Reox, 1 mM DCA continuously
infused from the onset of reoxygenation. #P < 0.05 vs. pre-acute hypoxia in the same group; †P < 0.05 vs. DCA
Hypox/Reox at a given time point; &P < 0.05 vs. acute hypoxia in the same experimental group; ‡P < 0.05 vs.
control at a given time point.
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Table 1. Animal anthropometric and physiological characteristics
Body weight (g) Haemoglobin (g/L) Heart weight (mg) HW/BW (mg g−1) CF (mL min−1) CF (mL min−1 g−1)
Control 39.4 ± 0.7 101.1 ± 5.5 306.6 ± 10.4 7.8 ± 0.3 4.5 ± 0.3 14.9 ± 1.5
Chronic hypoxia 37.8 ± 0.4 173.9 ± 3.4∗ 305.1 ± 15.7 8.1 ± 0.4 4.9 ± 0.2 16.4 ± 1.4
Hypoxia/DCA 36.4 ± 0.4∗ 173.0 ± 3.1∗ 315.0 ± 11.9 9.0 ± 0.3 4.5 ± 0.3 14.3 ± 0.8
Values are means ± SEM (n = 8). HW/BW, heart weight/body weight ratio; CF, coronary flow. ∗P < 0.05 vs. control.
animals fed with vehicle (Table 1). Blood haemoglobin
concentration, heart mass and coronary flow rate were
not altered with DCA feeding. Hearts from chronically
hypoxic animals fed DCA had normal DP, slightly lower
heart rate (P = 0.024), but normal RPP (Fig. 2A–C) prior
to acute hypoxia. DCA protected hearts from chronically
hypoxic mice, as the end-hypoxic DP was greater in hearts
from DCA-treated chronically hypoxic mice than from
vehicle-fed animals (28.7 ± 3.5 vs. 15.3 ± 1.4 mmHg,
P = 0.01), and RPP was also increased (5900 ± 600 vs.
3300 ± 300 mmHg (beats min−1), P = 0.003). DCA
increased final recovery of RPP relative to vehicle-fed
chronically hypoxicmice, from 23± 6 to 50± 3% (Fig. 2C
and D, P = 0.001). This was largely as a consequence
of increased recovery of DP (Fig. 2A, P = 0.016). In
contrast to the maintained EDP seen with reoxygenation
in vehicle-fed chronically hypoxic hearts, DCA resulted
in reoxygenation EDP levels being no different to those
seen in normoxic controls (Fig. 2E). In summary,
DCA feeding during chronic hypoxia improved cardiac
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Figure 2. The effect of chronic hypoxia on cardiac function, hypoxic tolerance, and the effect of DCA
treatment during hypoxia
Developed pressure (DP) (A), heart rate (HR) (B), rate pressure product (RPP) (C), acute hypoxic tolerance (D) and
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function both during an acute hypoxic challenge and in
reoxygenation.
Chronic DCA treatment normalises cardiac glycolytic
flux and lactate efflux during reoxygenation
Chronic hypoxic housing increased cardiac glycolytic
flux by 41% relative to normoxic controls (Fig. 3A,
P= 0.024), but this was normalised by DCA. As expected,
the glycolytic rate increased 2.4-fold during acute hypo-
xia (P = 0.001) in normoxic control hearts, and the
rate at the end of acute hypoxia was no different in
chronic hypoxic animals irrespective of treatment with
DCA. However, when the glycolytic rate was expressed
relative to RPP (which was altered with chronic hypoxia –
Fig. 2C), DCA-treated hearts had a 42% lower glycolytic
rate at the end of acute hypoxia (P = 0.035). During
reoxygenation, chronically hypoxic hearts had 1.7- and
2.9-fold greater glycolytic rate relative to both normoxic
controls (P= 0.038) andDCA-treated chronically hypoxic
hearts (P = 0.001), respectively.
Cardiac lactate efflux was not altered with chronic
hypoxia with or without DCA (Fig. 3C). Acute hypoxia
resulted in a doubling of lactate efflux in hearts from
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chronically hypoxic animals, which was not affected by
DCA (P = 0.001). Lactate efflux normalised to cardiac
functionwas not different prior to acute hypoxia (Fig. 3D),
but acute hypoxia increased lactate efflux/RPP 1.5-fold
(P = 0.022), with similar increases in hearts from
chronically hypoxic animals. This was maintained during
reoxygenation, but lactate efflux/RRP was 54% lower in
hearts fromDCA-fed animals exposed to chronic hypoxia
compared to vehicle-fed animals (P = 0.007).
Chronic DCA treatment leads to acetyl group
accumulation
Cardiac PDC activity prior to acute hypoxia was unaltered
with chronic hypoxia with or without DCA (Fig. 4A),
and levels of PDK1 and PDK4 protein were also unaltered
across groups (data not shown). Acute hypoxia doubled
PDCactivity inhearts fromnormoxic animals (P=0.032),
but not in chronically hypoxic animals or in animals
DCA-treated in chronic hypoxia. Chronically hypoxic
animals treated with DCA had double the cardiac acetyl-
carnitine content prior to acute hypoxia compared to
vehicle-fed animals (Fig. 4B, P = 0.013). Consistent with
our findings from our first acute hypoxic study (Fig. 1E),
acetylcarnitine content fell by the end of acute hypo-
xia in all groups, and the high level of acetylcarnitine
with DCA treatment had returned to near-control levels
(P= 0.006). Acetylcarnitine content remained low during
reoxygenation under all experimental conditions.
Chronic DCA treatment preserves cardiac ATP and
glycogen content during acute hypoxia
Chronichypoxiadidnot alter baseline cardiacATPcontent
(Fig. 5A), and this was not affected byDCA. Acute hypoxia
reduced cardiac ATP by 37% in normoxic control hearts
(P = 0.001) and by 44% in hearts from chronically hypo-
xic mice (P = 0.001), but chronic DCA feeding preserved
28%moreATPcompared tohearts fromchronically hypo-
xic animals (P = 0.018). Cardiac ATP was not altered
within any group with reoxygenation. Consistent with
these observations, the cardiac TAN pool (Fig. 5B) was
greater in DCA-treated animals, both at end-hypoxia
and following reoxygenation (main effect, P = 0.034).
The energy charge of the cell was unaltered with either
chronic hypoxia or DCA treatment (Fig. 5C). Acute hypo-
xia resulted in a fall in energy charge in control hearts
(9%, P = 0.006) and was unaltered with chronic hypoxia
or DCA treatment. Energy charge remained low in control
hearts with reoxygenation, but recovered slightly in hearts
previously exposed to chronic hypoxia (9% relative to
end-hypoxia, P = 0.039) or DCA treatment (8% relative
to end-hypoxia, P= 0.001). Cardiac glycogen content was
no different following chronic hypoxia or DCA treatment
compared to normoxic controls. Acute hypoxia resulted
in a 41% fall in cardiac glycogen content in normoxic
animals (Fig. 5D, P = 0.002), with no significant effect
of chronic hypoxia, but DCA spared cardiac glycogen
(P = 0.007) compared to hearts from normoxic animals.
This difference was maintained during reoxygenation
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(P = 0.022 vs. normoxic controls), but also compared
to hearts from vehicle-fed chronically hypoxic animals
(P= 0.007).Cardiacmuscle lactate contentwas not altered
with either chronic hypoxia or chronic hypoxia with DCA
treatment (Fig. 5E). However, at the end of acute hypo-
xia lactate content was 20% less in hearts from chronically
hypoxicmice compared to normoxic controls (P= 0.038),
and 47% less in hearts from chronically hypoxic, DCA-fed
animals (P= 0.001). These responseswere not alteredwith
reoxygenation. Total creatine was unaltered with chronic
hypoxia or DCA treatment (Fig. 5F), but DCA treatment
in chronic hypoxia preserved total creatine during acute
hypoxia (45% greater than normoxic control or chronic
hypoxia groups, P = 0.001) and following reoxygenation
(40% greater than normoxic control or chronic hypoxia
groups, P = 0.002).
Discussion
This study aimed to identify the metabolic physio-
logy of hypoxic cardiac tolerance in response to the
pharmacological activation of PDC and its flux with
dichloroacetate. Information on the role of the PDC
in cardiac adaptation to chronic hypoxia is scarce. It
is unclear how the chronically hypoxic heart responds
functionally and metabolically to acute stress following
hypoxic adaptation,with a variety of results reported in the
literature, and the role of the PDC is undetermined. In an
acute hypoxic challenge, DCA-mediated PDC activation
did not improve function, probably due to the fact that
a large increase in PDC activation was not matched by
a similar increase in flux through the PDC reaction.
However, in the chronically hypoxic heart, where the
tolerance to acute hypoxia was substantially reduced,
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simultaneous DCA-mediated activation of the PDC with
chronic hypoxia stockpiled acetylcarnitine, a marker of
elevated PDC flux. When subsequently exposed to acute
hypoxia, this acetylcarnitine surplus was exhausted. The
use of these acetyl groups resulted in improved function
both during acute hypoxia and during reoxygenation.
Acute hypoxia
We first assessed how activation of the PDC via DCA
infusion affected the cardiac response to acute hypo-
xia. Acute hypoxia resulted in considerable cardiac
damage, as determined by the impaired recovery during
reoxygenation. Despite activating the PDC 4-fold with an
infusion of DCA during acute hypoxia, limited evidence
of flux was apparent, with only a small increase in
acetylcarnitine content. This did not improve cardiac
function, which was also true of DCA infusion during
reoxygenation alone – acetylcarnitine accumulation was
also limited in this condition. These findings contrast with
the positive effects of DCA infusion reported in global
ischaemia experiments,where recoverywas improvedwith
DCA infusion at the onset of reperfusion (McVeigh &
Lopaschuk, 1990; Randall et al. 1998;Wambolt et al. 2000).
One difference between these ischaemic protocols and the
acute hypoxic protocol used in our studies is that contra-
ctile function was sustained throughout hypoxia, albeit
at 20% of baseline function, in contrast to ischaemic
studies, where function is typically reported as negligible
(Schroeder et al. 2009), even when some coronary flow
was maintained (Sidell et al. 2002). During hypoxia, this
functionwas supported by significant fatty acid oxidation,
indicating that a significant portion of ATP production
was via oxidative phosphorylation, and it may be that a
change in redox status subsequently affected recovery from
acute hypoxia. The infusion of DCAduring reoxygenation
suppressed fatty acid oxidation – the mechanism for
this may be via reduced free carnitine content due to
acetylation of the carnitine pool (Stephens et al. 2007),
or increased malonyl-CoA levels (Saddik et al. 1993).
As recovery of function was unaltered, cardiac energy
supply was presumably compensated for by increased
carbohydrate metabolism.
Chronic hypoxia
Chronically hypoxic hearts were functionally less tolerant
of subsequent acute hypoxia, during the acute hypoxic
period, and exacerbated by reperfusion. Reduced hypoxic
tolerance of the intact beating rat heart following 2 weeks
of housing in 10% F iCO2 has been reported previously
(Milano et al. 2002), although themechanisms underlying
such impairment were not investigated. In contrast, others
report improved tolerance following hypoxic exposure
in primary cardiomyocytes exposed for 48 h (Silverman
et al. 1997), or in papillary muscle exposed to hypo-
xia for up to 74 weeks (La Padula & Costa, 2005), with
improvements observed after 1 week. The cause of the
increased damage seen in our experiments does not appear
to be via alterations in substrate metabolism, although we
found an increased reliance on glycolysis in reoxygenation,
consistent with metabolic inflexibility following chronic
hypoxia (Cole et al. 2016).
Chronic hypoxia does not result in reduced
PDC function
We hypothesised that sustained in vivo hypoxia would
result in a fall in PDC activity and flux, thus limiting
mitochondrial respiration and attenuating reactive oxygen
species generation (Kim et al. 2006; Papandreou et al.
2006). However, we did not observe any modification
of PDC activity or flux following 21 days of hypoxia.
Le Moine et al. (2011) showed that PDC activity of
murine skeletal muscle fell following 24 h of exposure
to the equivalent of 13% F iO2 , but had recovered with
7 days of sustained hypoxic exposure. This mechanism
is possibly due to the transient nature of the oxygen
sensing transcription factor, hypoxia-inducible factor 1α
stabilisation, also shown by Le Moine et al. (2011), pre-
viously reported by Stroka et al. (2001) in brain, liver
and kidney, and demonstrated in beating cardiac cells by
Ambrose et al. (2014). Hence it would appear impairment
of PDC function is part of the early cellular response to
hypoxia, with PDC function returning to normal with
sustained restriction of oxygen.
The role of acetylcarnitine in hypoxic tolerance
Treatment with DCA during chronic hypoxia improved
cardiac function, both during acute hypoxia and in
reoxygenation. DCA treatment has been seen to have
beneficial effects on systolic function following ventricular
fibrillation (Azam et al. 2015) and diastolic function in
the diabetic heart (Le Page et al. 2015), where PDC flux
is impaired. In our study, chronic treatment of the hypo-
xic heart with DCA resulted in evidence of increased flux
through the PDC reaction, with a doubling of cardiac
acetylcarnitine content. In situations where acetyl-CoA
production exceeds utilisation in the Krebs cycle, acetyl-
carnitine accumulates in the cytosol via the actions of
carnitine acetyl transferase (CAT) (Constantin-Teodosiu
et al. 1991a), thereby acting as an acetyl group buffer.
Schroeder et al. (2012) found that aroundhalf of all cardiac
acetyl-CoA produced via pyruvate is cycled through CAT
before being committed to the TCA cycle, supporting the
idea that the CAT system is doing more that acting as a
disposal route for excess acetyl-CoA.
It has been shown previously that increasing the
acetylcarnitine pool prior to the onset of contraction
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under ischaemic conditions can improve skeletal muscle
fatigue resistance (Timmons et al. 1997; Roberts et al.
2005) by compensating for an acetyl group deficit at
the onset of muscle contraction that exists as a result of
inertia in activation of the PDC (Greenhaff et al. 2002).
Loss of CAT function also prevents improvements in
skeletal muscle performance with increased acetyl group
availability (Seiler et al. 2015).With sustained contraction,
acetylcarnitine content increases (Roberts et al. 2005),
as mitochondrial acetyl-CoA levels are increased via
irreversible oxidative decarboxylation of pyruvate via
the PDC and increased oxidation of fatty acids. With
prolonged exercise and the development of limitation in
substrate supply, skeletal muscle acetylcarnitine levels fall
(Watt et al. 2002). In our cardiac study, acetylcarnitine
fell during acute hypoxia, possibly as a result of allosteric
inhibition of PDC flux via a change in the redox state,
and the subsequent use of acetylcarnitine as a supply
of acetyl-CoA to support a limited amount of substrate
oxidation. The mismatch between activation of PDC, and
PDCflux, has beenpreviously shown tooccur in ischaemic
skeletalmuscle, where the inability to reoxidiseNADHwas
shown to have no effect on the activity of the PDC, but
inhibited its flux and hence accumulation of acetyl groups
(Constantin-Teodosiu et al. 1993).
Our finding that increasing acetyl group availability
improves cardiac function supports the hypothesis that
acetylcarnitine buffers acetyl-CoA levels (Constantin-
Teodosiu et al. 1991a; Seiler et al. 2015). This hypothesis
is based primarily on work on skeletal muscle, and
building on previous work on cardiac ischaemia (McVeigh
& Lopaschuk, 1990; Greenhaff et al. 2004), we believe
our study to be the first to provide evidence that
increasing acetyl group availability improves cardiac
function during and following hypoxia. The stockpile of
cardiac acetylcarnitine we observed following prolonged
DCA administration concurrent with chronic hypoxia
was exhausted by the end of 30 min of acute hypo-
xia. The significant oxidative phosphorylation evident
throughout this acute hypoxic period suggests that this
acetylcarnitine was being used to maintain acetyl-CoA
for use in the Krebs cycle, thus sparing glycogen and
maintaining ATP, maintaining cardiac function during
hypoxia and reducing hypoxic damage.
Summary
We found in this study that chronic hypoxia exacerbated
the damage from subsequent acute hypoxia, but that this
was counteracted by activation of PDC during chronic
hypoxic exposure. This improved cardiac performance
was associated with stockpiling of PDC-mediated acetyl-
carnitine, which was depleted during acute hypoxia,
and reduced hypoxic damage. This finding suggests that
activation of PDC may have therapeutic potential in
cardiac disease with a hypoxic component.
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